In the mammalian heart, a variety of injuries, ranging from ischemia to inflammatory diseases or maladaptive responses, can lead to massive or sporadic loss of myocardial cells. After an infarction, cardiomyocyte death triggers a series of molecular and cellular events that culminate in an inflammatory response, fibroblast accumulation, the production of extracellular matrix, and scarring. In humans, fibrous scar tissue may cause severe contractile dysfunction, even to the point of heart failure, and conventional pharmacological treatments are frequently inadequate. Regenerating the heart has thus become a major challenge, and its potential impact in experimental medicine justifies the growing number of strategies and approaches currently being investigated to achieve therapeutically significant cardiac regeneration.

It is generally agreed that soon after birth, mammalian cardiomyocytes stop dividing and make a transition from hyperplastic to hypertrophic growth. Cell cycle activity is low in adult cardiomyocytes, and their inability to reactivate mitosis may explain why tumors of the myocardium are very rare, and why immortalized cardiomyocyte lines have never been obtained spontaneously. Although regenerating the heart by stimulating the reactivation of cardiomyocyte proliferation remains an attractive prospect, it is probably not enough to bring about a complete functional recovery. Instead, a wide variety of exogenous stem cells have been considered as possible cardiac regeneration aids, both in experimental models and in human trials. Skeletal myoblasts, bone marrow--derived hematopoietic and mesenchymal stem cells, and circulating endothelial progenitor cells all have been tested, but the results have generally been disappointing (for review see [@bib10]). Transient improvements in heart function have been reported; however, it is now clear that this is caused by paracrine mechanisms acting on host tissue, not by transdifferentiation of exogenous cells into cardiomyocytes ([@bib10]). Support for the ambitious goal of cardiac regeneration has come from the recent finding that the adult mammalian heart contains cardiogenic stem and progenitor cells ([@bib3]; [@bib41]; [@bib37]; [@bib34]). Why these cells cannot arrest or reverse progressive myocardial loss during disease remains to be explained.

In this review, we first analyze the ability of some vertebrates, specifically zebrafish and salamanders, to efficiently regenerate damaged cardiac tissue. We then focus on the mammalian heart, which responds to cardiac tissue damage not by regeneration but by scarring. In particular, we reconsider the biology of two key cardiac cells in close structural partnership, the cardiomyocyte and the interstitial fibroblast, with a view to identifying the barriers to efficient cardiac regeneration in mammals. In this context, we also reexamine and critically evaluate the role of mammalian cardiac stem and progenitor cells.

The unquestionable regeneration potential of zebrafish and salamander hearts
============================================================================

Unlike wound healing, which is common to all animals, the capacity for regeneration varies between and within species and phyla. Species with the potential to regenerate the heart essentially use two strategies; progenitor cell proliferation, or dedifferentiation and subsequent division of the cells surrounding the injury (here and elsewhere we use the term "dedifferentiation" to mean the condition whereby a cell regresses from a fully differentiated form into a simpler state, an event coupled with cell cycle reentry). Heart regeneration is remarkably efficient in adult zebrafish, as demonstrated by experiments involving resection of the ventricular apex ([@bib47]). New cardiomyocytes originate from progenitor cells that express epicardial markers, such as raldh2 and Tbx18 ([@bib46]). Zebrafish cardiac progenitor cells are successfully driven to regenerate by interaction with the epicardium, the thin epithelial layer enveloping the chambers. The epicardium is not simply a bystander to myocardial regeneration after injury; rather, it exhibits a rapid and robust proliferation. Cells close to the resection site invade the regenerating tissue through a process strongly reminiscent of the epithelial-to-mesenchymal transition occurring in the developing heart, contributing endothelial and smooth muscle cells for the new vessels ([@bib28]). The epicardium also regulates the addition of new myocardial and epicardial cells during homeostatic cardiac growth ([@bib62]), but it remains unclear whether newly formed cardiomyocytes originate from this source or from progenitor cells after epicardial-mediated activation.

Epicardial and myocardial cross-talk is mediated by FGF signaling, and inhibiting the FGF receptor blocks cardiac regeneration ([@bib28]). The same signaling pathway guides cardiac progenitor cells in regulating heart size, atrial-to-ventricular proportions, and ventricular cardiomyocyte numbers at later stages of development ([@bib33]). Other signals may cooperate with FGF to induce myocardial proliferation, as suggested by the up-regulation of growth factors (PDGF, insulin-like growth factor, and Delta-Notch) during regeneration ([@bib46]).

In adult salamanders and newts (*Notophthalmus viridescens*), larval axolotl (*Amblystoma mexicanum*), and teleost fish (*Danio rerio*, zebrafish), regeneration after heart apex amputation involves blastema formation; i.e., the accumulation of dedifferentiated cells near the edge of the lesion. These blastema cells originate either from the dedifferentiation of resident cardiomyocytes (salamanders) or from resident progenitor cells (zebrafish). In the newt, dividing cardiomyocytes partially disassemble sarcomeric structures ([@bib56]) and revert to cells that can renew and also differentiate into other cell types on appropriate inductive signals ([@bib25]). After injury, 75% of cultured cardiomyocytes synthesize DNA and 60% progress to karyokinesis; about half of the latter divide, whereas the other half generate multinucleated cells ([@bib4]), which indicates a heterogeneity in relation to the regulation of cell division. Dedifferentiation of preexisting cardiomyocytes has also been postulated for the zebrafish heart, but it has not been supported by experimental evidence ([@bib28]).

The questionable regeneration potential of the mammalian heart
==============================================================

At variance with zebrafish and salamanders, the uninjured mammalian myocardium is traditionally considered incapable of self-renewal. Using a sophisticated and very elegant inducible transgenic mouse model, [@bib19] confirmed this hypothesis. They also showed, however, that the adult heart achieves a modest, but nonetheless convincing, self-renewal after injury that was attributed to a pool of resident stem cells. Over the past few years, several reports have described putative cardiac stem and progenitor cells in the adult heart. We give a brief account here of the major contributions in this field, referring the reader to several recent papers for a thorough overview of the topic ([@bib42]; [@bib50]; [@bib67]).

Three distinct cardiac stem cell populations have been described in the adult myocardium, based on the expression of the surface markers c-kit (tyrosine kinase receptor-1), Sca-1, and the ATP-binding cassette transporter (also called the "side population" or SP because these cells pump out Hoechst stain; [@bib3]; [@bib41]; [@bib37]; [@bib34]). The best characterized of these cells are those expressing c-kit. [@bib3] cloned and expanded these cells from different species, and obtained significant cardiac regeneration ([@bib3]), angiogenesis, and arteriogenesis ([@bib58]) after their injection into the infarcted myocardium. Despite these findings, the ability of c-kit^+^ cells to activate and support spontaneous regeneration in the adult heart remains highly controversial. All studies are based on the transplantation of very large numbers of c-kit^+^ cells into the injured heart, so a cell lineage approach is required to address this issue conclusively. Two other major concerns about these cells are their precise localization and number. Using genetically engineered mice expressing GFP under the c-kit promoter, [@bib11] demonstrated that c-kit^+^ cardiac cells decline markedly in the first two postnatal weeks and almost disappear after ten weeks.

Numerous efforts have been put forward in the last few years to investigate the nature of progenitor cells responsible for heart development because it is well established that the multiple programs controlling the onset of cardiogenesis are recapitulated in heart disease. Fate-mapping studies have demonstrated that the developing heart contains Isl1^+^/Nkx2.5^+^/Flk-1^+^ multipotent mesodermal progenitors that can give rise to cardiac muscle, smooth muscle, and endothelial lineages ([Fig. 1](#fig1){ref-type="fig"}; [@bib40]; [@bib21]; [@bib66]). Isl1-marked cells have been identified in the secondary heart field ([@bib8]; [@bib27]), the embryological anlagen from which the atria, outflow tract, and most of the right ventricle develop ([@bib22]). However, a recent study suggests that these cells contribute to cardiac, smooth muscle, and endothelial cells in all four cardiac chambers ([@bib31]; for review see [@bib26]). Additionally, a bipotent Nkx2.5^+^/c-kit^+^ progenitor isolated from the developing mouse embryo has been shown to generate cardiac and smooth muscle cells in vitro and in vivo ([@bib66]).

![**Schematic representation of stem and progenitor cells in the developing and juvenile/adult rodent heart.** CM, cardiomyocytes; EC, endothelial cells; SMC, smooth muscle cells.](JCB_200810094_RGB_Fig1){#fig1}

A second potential source of stem cells in the developing heart is the epicardium ([Fig. 1](#fig1){ref-type="fig"}). Investigations on the fate and differentiation of epicardium-derived cells (EPDCs) indicate that they generate smooth muscle cells and fibroblasts of the coronary vessels, and the interstitial fibrous skeleton of the heart ([@bib63]). In avians, the origin of endothelial cells in the coronary vessels is still being debated ([@bib45]), as is the myocardial potential of EPDCs ([@bib38]; [@bib39]; [@bib13]). In the developing mouse heart, recent data have shown that epicardial progenitors expressing Tbx18 ([@bib9]) and Wt1 ([@bib69]), possibly derived from a common Isl1^+^/Nkx2.5^+^ ancestor ([@bib31]), generate new cardiomyocytes.

It would be tempting to hypothesize that the essential properties of the epicardium can be recapitulated in the adult heart and used for regeneration. Epicardial c-kit^+^ multipotent cells expressing Nkx2.5 and GATA4 have been identified in the human and mouse adult heart as a minority of all the epicardial cells. Keeping the pericardial sac intact during infarction by ligating the coronary artery prevents myocardial tissue from deteriorating and results in foci of cardiac regeneration, as demonstrated by the presence of a small population of lentivirus-labeled epicardial cells expressing the cardiac marker α-sarcomeric actin ([@bib30]). Other reports indicate that EPDCs do not acquire a cardiomyocyte phenotype when transplanted into infarcted mouse heart ([@bib64]). To summarize, it seems reasonable to suggest that the mammalian epicardium is composed of heterogeneous populations of cardiogenic progenitors with distinct potentials for differentiation.

As in the zebrafish, the epicardium has a crucial stimulatory role essential for proper development, and possibly also for regeneration. One of the factors that influences this instructive role is thymosine β4 (Tβ4), a G-actin monomer-binding protein implicated in cytoskeleton reorganization. Tβ4 secreted from the developing myocardium stimulates the proliferation, differentiation, and inward migration of epicardial cells ([@bib52]). Similarly, Tβ4 is responsible for enhanced cardiomyocyte survival, and consequently for cardioprotection ([@bib6]; [@bib52]), in the event of injury.

A third, and potentially more useful, source of cardiac stem and progenitor cells may be the vasculature. Vessel-associated progenitor cells, called mesoangioblasts, have recently been identified in the juvenile mouse heart ([Fig. 1](#fig1){ref-type="fig"}). These cells express endothelial and pericyte markers, and are committed to cardiac differentiation in vitro and in vivo ([@bib12]). Because they retain a remarkable potential for cardiac differentiation when implanted in the secondary heart field of a chick embryo, it is reasonable to postulate that they are recruited to become cardiomyocytes during postnatal growth. It is worth noting that cardiac progenitor cells, which are identifiable from their ability to grow as cardiospheres, have been obtained using similar technical procedures from both adult mouse heart explants ([@bib37]) and human endomyocardial ventricular biopsies ([@bib53]). In the developing heart, there may be a cell network that, for regeneration purposes, connects the epicardium to the myocardium via the coronary vessels, as shown in [Fig. 2](#fig2){ref-type="fig"}. Further investigations are needed to establish whether such a network persists in postnatal life.

![**Schematic representation of the hypothetical link between epicardial progenitor cells and the mesoangioblast/pericyte cell population surrounding the coronary vessels.** A subpopulation of epicardial cells delaminates from the subendocardial space and migrates to the underlying myocardium using the vascular network as a guide. These progenitors may also be able to generate the intramyocardial clusters of c-kit^+^/Sca-1^+^ stem and progenitor cells that persist into adulthood, but alternative sources of these cells cannot be excluded. CM, cardiomyocytes.](JCB_200810094_RGB_Fig2){#fig2}

In conclusion, the mammalian heart contains a plethora of potential stem and progenitor cells, but their persistence in adulthood is still unclear. Isl1^+^ cells progressively disappear in the postnatal heart except where the cardiac autonomic nervous system intersects with the cardiac conduction system ([@bib26]). Vessel-associated progenitor cells, in contrast, persist in the postnatal heart, but their number and potential to regenerate over time has yet to be determined. Cardiac c-kit+ stem cells are found in adult myocardium, but it is unclear whether they are a remnant of development or are recruited postnatally. In addition, it is possible that some of the many progenitor cells found in the developing heart have simply not yet been identified in the postnatal heart.

The fundamental questions in the field are as follows. What are the restrictions to cardiac regeneration and are they species-specific? Can these evolutionarily imposed restrictions be removed? In answer to these questions, two barriers to regeneration in the mammalian heart have been identified: one involving the capacity of cardiomyocytes to proliferate, the other lying in the interactions between cardiomyocytes and interstitial cells.

The intrinsic resistance of mammalian cardiomyocytes to division
================================================================

Mammalian cardiomyocytes undergo cell cycle withdrawal during late gestation. A final round of incomplete division occurs after birth and results in binucleated or multinucleated cardiomyocytes. Cardiomyocytes can reactivate the cell cycle after various pathological stimuli such as a hypertrophic response ([@bib43]; [@bib48]; [@bib59]). This reactivation is transient and does not always progress to mitosis. Therefore, the histological detection of cell cycle and DNA synthesis markers, such as Ki67, histone H3 phosphorylation, and BrdU incorporation, does not necessarily mean cell division. Only karyokinesis and cytokinesis can be accepted as definitive proof of cardiomyocyte proliferation.

Using a combination of in vitro and in vivo models, it has been demonstrated that the myocardial cell cycle can be reprogrammed, at least to some degree. The majority of proteins that affect the cell cycle activity of cardiomyocytes are involved in transit through the restriction point. CDK4 and CDK6, and their activating partners D-type cyclins ([@bib44]), the phosphorylation state of the retinoblastoma pocket protein ([@bib32]), and the subsequent activation of the transcription factor E2F, have been manipulated to induce cardiac cell division. Striking evidence of the functional impact of reactivating cardiomyocyte proliferation comes from the demonstration that cardiac-specific overexpression of cyclin D2 improves cardiac function after infarction in mice ([@bib16]).

Novel signaling pathways that control cardiac cell division have recently been revealed with a view to developing new pharmacological strategies to counteract myocardial dysfunction. The extracellular matrix protein periostin reactivates mitosis in mouse cardiomyocytes via β-integrin and phosphoinositide 3-kinase ([@bib24]), but why high periostin levels in the infarcted myocardium are unable to promote cell cycle activation in the resident cardiomyocytes remains to be explained.

Cardiac cell division is accompanied by structural modifications, resulting mainly in sequential myofibrillar disassembly and reassembly ([@bib1]). This complex process might provide a mechanistic explanation as to why postnatal cardiomyocytes stop dividing as the contractile apparatus matures. It may be that dedifferentiation favors cell cycle reentry, as in naturally dividing newt cardiomyocytes ([@bib4]). Indeed, dedifferentiated cardiomyocytes (characterized by disassembly of the contractile apparatus, the acquisition of fetal markers, and anomalous mitochondria) have been seen in human diseases such as chronic hibernating myocardium or chronic atrial fibrillation, and in the border zone of infarction ([@bib17]). We have found that adult cardiomyocytes cocultured in the presence of cardiac fibroblasts undergo dedifferentiation and cell cycle reentry ([@bib69]). The fine-tuning that enables cell cycle progression and completion after dedifferentiation remains to be elucidated.

Regeneration versus scarring
============================

The differing abilities of zebrafish, salamander, and mammals to generate new cardiomyocytes might also depend on the microenvironment. A comparative discussion on the influence of the microenvironment on cardiac regeneration is complicated because different types of injury have been studied in different species. In mammals, cardiac regeneration has been studied mainly in acute or chronic ischemia, or ischemia/reperfusion induced by coronary artery ligation. In newt and zebrafish, the model used is partial cardiac amputation because zebrafish have only subepicardial vessels that open into lacunes ([@bib20]), and the newt has no coronary vessels at all.

Fibroblast distribution also varies: fibroblasts account for the majority of nonmuscle cells in mammals, but they are rare in zebrafish and newts, and occur randomly interspersed within the subepicardial layer. On the whole, the myocardial histology of these lower vertebrates is quite simple and its 3D structure resembles that of the trabeculated fetal heart of mammals. Tissue organization is more complex in the adult mammalian heart: single cardiomyocytes are in contact with capillaries and interconnected with fibroblasts ([Fig. 3](#fig3){ref-type="fig"}). Fibroblasts have an important role in developing the local and global myocardial response to mechanical, electrical, and chemical signals generated by cardiac damage ([@bib2]).

![**Myocardial structure in different species.** Hematoxylin and eosin staining shows tissue organization in zebrafish (A), axolotl (C), and rat (E) hearts. Vascular-specific GFP expression in transgenic *fli1* (*friend leukemia integration 1*)-GFP zebrafish ([@bib70]) or immunostaining with specific antibodies show the distribution of the vascular network in these species. Zebrafish contain epicardial vessels (B, arrows) and endocardial cells that circumvent the cardiomyocytes (B′). Axolotl have no epicardial vessels, whereas endocardial cells expressing the von Willebrand factor (vWf) surround the cardiomyocytes (D). In the rat, the coronary vessels deepen into the myocardium, as shown by staining with antibodies to CD31 (endothelial marker) and SMA (smooth muscle cell marker). (right) Two schematic representations show the positional relationships between cardiomyocytes (CM) and surrounding endothelial (EC) or endocardial (ENC) cells, fibroblasts (F), and pericytes (P). B, B′, D, and F are confocal images of tissue sections. Bars: (A, C, E, and F) 100 µm; (B and D) 50 µm.](JCB_200810094_RGB_Fig3){#fig3}

The modulation of fibroblast activity can impact the balance of regeneration versus healing after cardiac injury. In zebrafish and newt, regeneration is accompanied not only by progenitor cell activation or cell dedifferentiation, but also by the up-regulation of genes encoding matrix metalloproteinases ([@bib61]; [@bib29]) and tissue inhibitors of matrix metalloproteinases ([@bib54]). In limb reconstruction, these genes are known to control extracellular matrix remodeling and regeneration. After heart injury in zebrafish, fibroblasts and cardiomyocytes are activated in a reciprocal manner. When cardiogenesis is blocked by a dominant-negative FGF receptor or mutation of the *Msp1* mitotic dominant checkpoint kinase, fibrin is retained, and a collagen-rich scar forms ([@bib47]; [@bib46]). This indicates that regeneration and repair sense each other and that the balance can be tipped toward one or the other, even when evolution has preserved the genetic capacity for regeneration. It also suggests that the extensive, well-organized network of fibroblasts in the mammalian heart is, by itself, an unfavorable condition for regeneration purposes for both cardiac stem cell differentiation and cardiomyocyte division.

A second major player in the damaged myocardium is the immunoinflammatory response. Although this response gives the injured heart the chance to surround the damaged area with granulation tissue and extracellular matrix, thus limiting expansion of the injured area, it can damage the surviving cardiomyocytes and cardiac stem cells. Salamander and zebrafish have innate immunity but incomplete adaptive immunity. It has been postulated from experiments in limb reconstruction that this less sophisticated adaptive immunity may be involved in conferring a marked regenerative potential to these species ([@bib15]; [@bib14]; [@bib36]). Unfortunately, studies on cardiac regeneration in newt/axolotl and zebrafish have failed to provide a detailed analysis of the inflammatory response. Blocking inflammation would be particularly interesting in zebrafish, for which mutants with an aberrant accumulation or deficiency of some inflammatory cells are available ([@bib35]).

Finally, the immature immunoinflammatory response and limited number of fibroblasts might also explain the great potential for regeneration of the mammalian heart in its early stages of development ([@bib5]). If a 14-d-old fetal mouse heart is explanted, surgically damaged, and kept in serum-free medium as an organ culture, its tissue architecture is rapidly reestablished with no inflammatory response or scarring. By 18 or 22 d of gestation, fibroblasts and myofibroblasts have accumulated in the heart, and the trabeculated structure of the ventricle has been replaced by compact myocardium. If the organ is explanted at this point in development, a wound will heal by scarring.

Concluding remarks and future directions
========================================

We reasoned that the differing regenerative capabilities of hearts from teleost fish and urodele amphibians compared with mammals stems from the existence of species-specific barriers. In particular, adult mammalian cardiomyocytes have an inherent inability to regenerate, either via stem cell--mediated mechanisms or by reentry of the cell cycle, and, additionally, they show a marked interstitial response. We suggest that the limited regeneration potential of the mammalian heart is caused by an evolutionary prioritization of hemostasis and fibrosis. Bleeding from the heart in a high-pressure circulatory system, which is practically unique to higher vertebrates, can seriously jeopardize survival. Selective pressure probably favored the more rapid fibrous healing response because survival would be compromised in the time it took to seal the defect by regeneration. Small vertebrates have a low-pressure circulatory system and incompletely oxygenated blood. The fetal cardiac microenvironment is characterized by a low oxygen tension in mammals as well, in contrast with the high oxygen-based metabolic demand of the postnatal heart. Because progenitor cell activation requires low oxygen levels in the microenvironment ([@bib51]), the mammalian adult heart may be inherently incapable of activating its own resident cardiogenic progenitors after injury.

Cardiomyocyte reentry in the cell cycle.
----------------------------------------

Cardiomyocyte proliferation could provide a mechanism for cardiac regeneration; however, it is unclear whether it is better for cardiomyocytes to revert to proliferating progenitors or to dedifferentiate back to immature cardiomyocytes that should be capable of one or more cell divisions. The former option would enable them to proliferate in abundance and become pluripotent; the latter would have a limited effect, but could prevent tumorigenic outcomes and might also favor cell--cell contact and integration with preexisting tissue.

Evidence from infarcted hearts of MHC-cycD2 transgenic mice demonstrated that cardiomyocyte cell cycle reactivation resulted in newly formed myocardium that participated in a functional syncytium with surviving myocardium from outside of the damaged zone ([@bib16]).

Cardiac stem cell identification.
---------------------------------

Cardiac stem cells remain an attractive possibility for regeneration, but the major identifying criteria for these cells in adult heart need to be fixed. First, clonogenic, self-renewal, and differentiation properties should be established in vitro and in vivo. In the latter case, a single cell should be transplanted into a cardiac region depleted of its own putative stem cell reservoir, as this is the gold standard that has been achieved in other systems such as skeletal muscle ([@bib49]) and bone marrow ([@bib7]). Second, if cardiac stem cells differentiate according to a hierarchical model, it is necessary to establish the transcriptional signature at different stages of quiescence, amplification, differentiation, and maturation. The combined expression of stem cell markers and cardiogenic transcription factors should be investigated using a cell lineage approach.

Fibrogenic response and fibroblast reprogramming.
-------------------------------------------------

Slowing the process of fibrosis may tip the balance of cardiac repair from healing to regeneration. Therapeutic options to counteract fibrosis by controlling the inflammatory response have been largely discouraging (for reviews see [@bib18]; [@bib65]); however, new approaches need to be attempted because the mechanisms involved in fibrogenesis are now known to be distinct from those pertaining to inflammation.

Cardiac fibroblasts might also be manipulated genetically to control their capacity for proliferation and transition toward myofibroblasts. Depressing fibroblast proliferation via the p53 and/or p16 retinoblastoma pathways leads to a reduced fibrosis in the liver in mice ([@bib23]), which suggests that a similar approach is worth testing in the heart. Other promising research involves reprogramming cardiac fibroblasts to obtain a different phenotype. It has recently been shown that somatic cells like adult fibroblasts can be reprogrammed to obtain a stable pluripotency using a combination of four transcription factors: c-myc, Oct-4, Sox-2, and Klf4 ([@bib55]). Cardiac fibroblasts might feasibly be reprogrammed to become contractile cells. We recently found that cardiac fibroblasts differ from those of other organs in that they already express a "repertoire" of cardiac genes, including GATA4 ([@bib69]). Whether this particular gene expression program makes them more responsive to cardiac reprogramming remains to be seen. It is worth adding that forcing the expression of myocardin in postinfarcted cardiac fibroblasts induces the expression of cardiomyocyte-specific proteins ([@bib60]).

On the whole, it is probably just as important to block fibroblast proliferation as to provide specific cues to induce myocardial proliferation. We need to reconsider regeneration as a process dependent on a concerted interplay between cardiomyocytes and the surrounding nonmyocardial cells, possibly as a structural and functional unit. It is interesting that in a mouse model of heart failure, specific inhibition of the interstitial fibrogenic response has an impact on cardiac hypertrophy and dysfunction, which suggests that fibroblasts control the cardiomyocyte response to pathological stimuli ([@bib57]). The complexity of this partnership varies considerably from one species to another, ranging from single cardiomyocytes with associated supporting capillaries and fibroblasts, as in mammals, to cardiomyocytes surrounded by endocardium with almost no fibroblasts or capillaries, as in zebrafish and axolotl ([Fig. 3](#fig3){ref-type="fig"}).

To summarize, the lesson that we have learned from comparison with regeneration-prone species is that the mammalian heart is inherently resistant to regeneration, possibly as a result of an evolutionary imposition. Therefore we propose that a combined approach encompassing all the three strategies described in this review, namely cardiomyocyte cell cycle reentry, stem cell mediated regeneration, and controlled fibrogenic response, has the greatest chance to succeed in restraining or even reversing the progression of cardiac deterioration in disease.
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